Novel Agent N-803 Safe, Effective for BCG-Unresponsive High-Risk NMIBC
Final results from a pivotal clinical trial show that the investigational agent N-803 combined with bacillus Calmette-Guérin (BCG) is safe and more effective than other intravesical and systemic options for high-risk nonmuscle-invasive bladder cancer (NMIBC)…